Gestational Glucose Intolerance and Birth Weight-Related Complications.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 19 01 2023
accepted: 13 04 2023
pmc-release: 01 09 2024
medline: 21 8 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

To evaluate the risks of large-for-gestational-age birth weight (LGA) and birth weight-related complications in pregnant individuals with gestational glucose intolerance, an abnormal screening glucose loading test result without meeting gestational diabetes mellitus (GDM) criteria. In a retrospective cohort study of 46,989 individuals with singleton pregnancies who delivered after 28 weeks of gestation, those with glucose loading test results less than 140 mg/dL were classified as having normal glucose tolerance. Those with glucose loading test results of 140 mg/dL or higher and fewer than two abnormal values on a 3-hour 100-g oral glucose tolerance test (OGTT) were classified as having gestational glucose intolerance. Those with two or more abnormal OGTT values were classified as having GDM. We hypothesized that gestational glucose intolerance would be associated with higher odds of LGA (birth weight greater than the 90th percentile for gestational age and sex). We used generalized estimating equations to examine the odds of LGA in pregnant individuals with gestational glucose intolerance compared with those with normal glucose tolerance, after adjustment for age, body mass index, parity, health insurance, race and ethnicity, and marital status. In addition, we investigated differences in birth weight-related adverse pregnancy outcomes. Large for gestational age was present in 7.8% of 39,685 pregnant individuals with normal glucose tolerance, 9.5% of 4,155 pregnant individuals with gestational glucose intolerance and normal OGTT, 14.5% of 1,438 pregnant individuals with gestational glucose intolerance and one abnormal OGTT value, and 16.0% of 1,711 pregnant individuals with GDM. The adjusted odds of LGA were higher in pregnant individuals with gestational glucose intolerance than in those with normal glucose tolerance overall (adjusted odds ratio [aOR] 1.35, 95% CI 1.23-1.49, P <.001). When compared separately with pregnant individuals with normal glucose tolerance, those with either gestational glucose intolerance subtype had higher adjusted LGA odds (gestational glucose intolerance with normal OGTT aOR 1.21, 95% CI 1.08-1.35, P <.001; gestational glucose intolerance with one abnormal OGTT value aOR 1.77, 95% CI 1.52-2.08, P <.001). The odds of birth weight-related adverse outcomes (including cesarean delivery, severe perineal lacerations, and shoulder dystocia or clavicular fracture) were higher in pregnant individuals with gestational glucose intolerance with one abnormal OGTT value than in those with normal glucose tolerance. Gestational glucose intolerance in pregnancy is associated with birth weight-related adverse pregnancy outcomes. Glucose lowering should be investigated as a strategy for lowering the risk of these outcomes in this group.

Identifiants

pubmed: 37539973
doi: 10.1097/AOG.0000000000005278
pii: 00006250-990000000-00849
pmc: PMC10527009
mid: NIHMS1906378
doi:

Substances chimiques

Glucose IY9XDZ35W2
Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

594-602

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007028
Pays : United States

Informations de copyright

Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial Disclosure: Camille E. Powe, MD, has received fees and royalties from Mediflix and UpToDate (Wolters Kluwer), respectively, for presentations and articles related to diabetes over which she had full control of content. The other authors did not report any potential conflicts of interest.

Références

N Engl J Med. 2005 Jun 16;352(24):2477-86
pubmed: 15951574
Environ Int. 2020 Sep;142:105875
pubmed: 32590283
Diabetes Care. 2002 Sep;25(9):1625-30
pubmed: 12196438
BMC Pediatr. 2003 Jul 8;3:6
pubmed: 12848901
Obstet Gynecol Clin North Am. 2021 Jun;48(2):325-337
pubmed: 33972069
Am J Obstet Gynecol. 2016 Sep;215(3):287-97
pubmed: 27133007
Obstet Gynecol. 2014 Dec;124(6):1128-1134
pubmed: 25415164
Am J Obstet Gynecol. 2010 Jun;202(6):654.e1-6
pubmed: 20510967
Epidemiology. 2019 Sep;30(5):624-632
pubmed: 31386644
Int J Gynaecol Obstet. 2023 Aug;162(2):578-589
pubmed: 36707062
Obstet Gynecol. 2004 Jan;103(1):148-56
pubmed: 14704259
Obstet Gynecol. 2018 Feb;131(2):e49-e64
pubmed: 29370047
N Engl J Med. 2009 Oct 1;361(14):1339-48
pubmed: 19797280
Diabetologia. 2010 Jan;53(1):89-97
pubmed: 19841891
Diabetes Care. 2023 Jan 1;46(1):83-91
pubmed: 36473077
Am J Obstet Gynecol. 1982 Dec 1;144(7):768-73
pubmed: 7148898
Ann Intern Med. 2013 Jul 16;159(2):123-9
pubmed: 23712381
Ann Nutr Metab. 2015;66 Suppl 2:14-20
pubmed: 26045324
Am J Obstet Gynecol MFM. 2021 Jul;3(4):100359
pubmed: 33757935
Diabetes Care. 2007 Jul;30 Suppl 2:S251-60
pubmed: 17596481
J Matern Fetal Med. 1998 Nov-Dec;7(6):292-5
pubmed: 9848695
J Matern Fetal Neonatal Med. 2021 Nov;34(22):3782-3789
pubmed: 34225532
Am J Obstet Gynecol MFM. 2023 Feb;5(2):100814
pubmed: 36396038
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Trends Endocrinol Metab. 2018 Nov;29(11):743-754
pubmed: 30297319
Am J Obstet Gynecol. 2004 Sep;191(3):700-7
pubmed: 15467528
J Obstet Gynaecol Res. 2022 Oct;48(10):2505-2513
pubmed: 35790472
Obstet Gynecol. 2019 Jun;133(6):1160-1166
pubmed: 31135729
Am J Obstet Gynecol. 2006 May;194(5):e16-9
pubmed: 16647890
N Engl J Med. 2021 Mar 11;384(10):895-904
pubmed: 33704936
Obstet Gynecol. 2014 Oct;124(4):863-866
pubmed: 25244460
Obstet Gynecol. 2017 May;129(5):e123-e133
pubmed: 28426618
N Engl J Med. 2022 Aug 18;387(7):587-598
pubmed: 36070709
JAMA. 2021 Aug 10;326(6):531-538
pubmed: 34374716
Obstet Gynecol. 2018 Sep;132(3):e87-e102
pubmed: 30134424
Diabetes. 1979 Dec;28(12):1039-57
pubmed: 510803
Obstet Gynecol. 2021 Jul 1;138(1):6-15
pubmed: 34259458
J Midwifery Womens Health. 2015 Jul-Aug;60(4):428-36
pubmed: 26255803
Am J Epidemiol. 2001 Sep 15;154(6):514-20
pubmed: 11549556
Int J Gynaecol Obstet. 2014 Apr;125(1):6-14
pubmed: 24529800
Obstet Gynecol. 1982 Oct;60(4):417-23
pubmed: 7121926
Epidemiology. 2007 Sep;18(5):544-51
pubmed: 17879426

Auteurs

Jacqueline Maya (J)

Diabetes Unit, the Department of Medicine, the Department of Pediatrics, the Biostatistics Center, and the Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, the Broad Institute of MIT and Harvard, the Department of Biostatistics, Harvard T.H. Chan School of Public Health, the Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, and the Division of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, Massachusetts; the Division of Endocrinology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; and the Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH